Alessandra Kobayati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alessandra Kobayati has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Haidar
Division of Experimental Medicine, Department of Medicine, McGill University, Montreal, QC, Canada.
2 shared publications - Anas El Fathi
Department of Biomedical Engineering, McGill University, Montreal, Canada
2 shared publications - Jean-François Yale
Division of Endocrinology McGill University Health Center Montreal Canada
2 shared publications Laurent Legault
Research Institute of McGill University Health Centre, Montreal, Canada
2 shared publications- Michael A. Tsoukas
Department of Medicine McGill University Montreal Quebec Canada
2 shared publications - Adnan Jafar
Department of Biomedical Engineering, McGill University, Montreal, Canada
1 shared publication
Latest Publications
- 15 December 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (4) , 872-882
Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes
Aims/hypothesis There is an unmet need for automated insulin adjustments for multiple daily injections in type 1 diabetes under unsupervised use. We aimed to assess the McGill decision support system (DSS), which comprises a Bayesian algorithm, by comparing its automated insulin adjustments with those made by endocrinologists. Methods We surveyed 13 Canadian endocrinologists who made mock insulin adjustments in three separate parts on retrospective participants’ data. Part A (weekly data) and part C (biweekly data) compared the recommendations from physicians with those of the algorithm. Part B evaluated intra-physician variability by comparing the recommendations made by the same physician over time based on an identical dataset to part A. Results In part A, the agreement rate (mean [SD]) on the direction of weekly adjustments between the algorithm and physicians was non-inferior to the agreement rate between physicians for prandial bolus (55% [5] vs 56% [7], respectively; p=0.006) and basal insulin (48% [6] vs 51% [11], respectively; p=0.037). Low full disagreement rates on weekly adjustments were also comparable between the pairs for prandial bolus (3.9% [2.3] vs 4.1% [2.3], respectively; p=0.006) and basal insulin (10.6% [4.6] vs 9.2% [7.1], respectively; p=0.23). Similar rates were observed for biweekly insulin adjustments in part C. When comparing intra-physician decisions in part A with those in part B, on average, physicians fully agreed with themselves 66% (SD 7) and 67% (SD 7) of the time for prandial bolus and basal insulin adjustments, respectively. Conclusions/interpretation The direction of insulin adjustments was comparable between physicians and the McGill algorithm. The large intra-physician variability further emphasises the subjective nature of insulin management. Graphical Abstract
- 15 December 2025
- Published by Springer Nature in Diabetologia
- Vol. 69 (4) , 872-882
Inter- and intra-physician variability in insulin injection adjustments compared with Bayesian algorithm recommendations in type 1 diabetes
Aims/hypothesis There is an unmet need for automated insulin adjustments for multiple daily injections in type 1 diabetes under unsupervised use. We aimed to assess the McGill decision support system (DSS), which comprises a Bayesian algorithm, by comparing its automated insulin adjustments with those made by endocrinologists. Methods We surveyed 13 Canadian endocrinologists who made mock insulin adjustments in three separate parts on retrospective participants’ data. Part A (weekly data) and part C (biweekly data) compared the recommendations from physicians with those of the algorithm. Part B evaluated intra-physician variability by comparing the recommendations made by the same physician over time based on an identical dataset to part A. Results In part A, the agreement rate (mean [SD]) on the direction of weekly adjustments between the algorithm and physicians was non-inferior to the agreement rate between physicians for prandial bolus (55% [5] vs 56% [7], respectively; p=0.006) and basal insulin (48% [6] vs 51% [11], respectively; p=0.037). Low full disagreement rates on weekly adjustments were also comparable between the pairs for prandial bolus (3.9% [2.3] vs 4.1% [2.3], respectively; p=0.006) and basal insulin (10.6% [4.6] vs 9.2% [7.1], respectively; p=0.23). Similar rates were observed for biweekly insulin adjustments in part C. When comparing intra-physician decisions in part A with those in part B, on average, physicians fully agreed with themselves 66% (SD 7) and 67% (SD 7) of the time for prandial bolus and basal insulin adjustments, respectively. Conclusions/interpretation The direction of insulin adjustments was comparable between physicians and the McGill algorithm. The large intra-physician variability further emphasises the subjective nature of insulin management. Graphical Abstract
- Open Access
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 8593
A Bayesian decision support system for automated insulin doses in adults with type 1 diabetes on multiple daily injections: a randomized controlled trial
Achieving optimal glycemic control remains challenging for many individuals with type 1 diabetes using multiple daily injections. We report results from a 12-week, open-label, randomized controlled trial evaluating a decision support system (DSS) consisting of a mobile application and a titration algorithm that provides weekly basal and prandial insulin recommendations. Eighty-four adults with type 1 diabetes and suboptimal glycemic control (HbA1c ≥ 7.5%) are randomized 1:1 to receive the DSS or a non-adaptive bolus calculator (control), alongside Freestyle Libre glucose sensors. The primary endpoint is change in HbA1c from baseline; secondary endpoints include additional glycemic and insulin-related metrics. The DSS reduces mean HbA1c from 8.6% (SD 1.1) to 8.1% (0.8) (p = 0.0002), while the control reduces HbA1c from 8.6% (1.0) to 8.5% (1.0) (p = 0.22); yielding a treatment effect of –0.40% (95% CI: –0.75 to –0.051; p = 0.025). There are no reported severe hypoglycemia or diabetic ketoacidosis events. Our DSS improves HbA1c in this population without compromising safety. ClinicalTrials.gov: NCT04123054 .
- 29 September 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 8593
Open AccessA Bayesian decision support system for automated insulin doses in adults with type 1 diabetes on multiple daily injections: a randomized controlled trial
Achieving optimal glycemic control remains challenging for many individuals with type 1 diabetes using multiple daily injections. We report results from a 12-week, open-label, randomized controlled trial evaluating a decision support system (DSS) consisting of a mobile application and a titration algorithm that provides weekly basal and prandial insulin recommendations. Eighty-four adults with type 1 diabetes and suboptimal glycemic control (HbA1c ≥ 7.5%) are randomized 1:1 to receive the DSS or a non-adaptive bolus calculator (control), alongside Freestyle Libre glucose sensors. The primary endpoint is change in HbA1c from baseline; secondary endpoints include additional glycemic and insulin-related metrics. The DSS reduces mean HbA1c from 8.6% (SD 1.1) to 8.1% (0.8) (p = 0.0002), while the control reduces HbA1c from 8.6% (1.0) to 8.5% (1.0) (p = 0.22); yielding a treatment effect of –0.40% (95% CI: –0.75 to –0.051; p = 0.025). There are no reported severe hypoglycemia or diabetic ketoacidosis events. Our DSS improves HbA1c in this population without compromising safety. ClinicalTrials.gov: NCT04123054 .
- 6 January 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (5) , 769-787
Glucagon‐like peptide ‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
Exogenous insulin has been the mainstay treatment for individuals living with type 1 diabetes (T1D). Although there has been tremendous growth in both pharmacological and technological advancements, insulin monotherapy has proven to be insufficient for maintaining optimal glycaemic targets for most adults with T1D. At present, there is still no breakthrough for the treatment of T1D. Adjunctive pharmacotherapies might therefore complement insulin management to achieve better glycaemic control, while possibly offering additional benefits. Recent interest in re‐purposing glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), a leading antihyperglycaemic medication class approved for type 2 diabetes, has prompted the field to seek extended potential for the T1D population. The adjunctive use of GLP‐1RAs has been at the forefront of T1D research, albeit with some conflicting trial findings to date. However, the potential of GLP‐1 agonism for T1D may have been underestimated, possibly from missed opportunities or categorized effects. Moreover, some GLP‐1RAs have demonstrated extra‐pancreatic potential with emerging multi‐organ protection involving the heart, kidneys, liver and brain in varied cohorts, which may bode well for the growing T1D profile of comorbid complications. This narrative review aims to summarize and critically appraise the current evidence‐based literature from large‐scale randomized controlled trials and closed‐loop system pilot studies that examined GLP‐1RAs as adjunctive therapy for T1D. Furthermore, we outline uncharted opportunities with GLP‐1 agonism using versatile approaches in selected T1D populations that may inspire and re‐direct future research in this field.
- 6 January 2022
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 24 (5) , 769-787
Glucagon‐like peptide ‐1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?
Exogenous insulin has been the mainstay treatment for individuals living with type 1 diabetes (T1D). Although there has been tremendous growth in both pharmacological and technological advancements, insulin monotherapy has proven to be insufficient for maintaining optimal glycaemic targets for most adults with T1D. At present, there is still no breakthrough for the treatment of T1D. Adjunctive pharmacotherapies might therefore complement insulin management to achieve better glycaemic control, while possibly offering additional benefits. Recent interest in re‐purposing glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), a leading antihyperglycaemic medication class approved for type 2 diabetes, has prompted the field to seek extended potential for the T1D population. The adjunctive use of GLP‐1RAs has been at the forefront of T1D research, albeit with some conflicting trial findings to date. However, the potential of GLP‐1 agonism for T1D may have been underestimated, possibly from missed opportunities or categorized effects. Moreover, some GLP‐1RAs have demonstrated extra‐pancreatic potential with emerging multi‐organ protection involving the heart, kidneys, liver and brain in varied cohorts, which may bode well for the growing T1D profile of comorbid complications. This narrative review aims to summarize and critically appraise the current evidence‐based literature from large‐scale randomized controlled trials and closed‐loop system pilot studies that examined GLP‐1RAs as adjunctive therapy for T1D. Furthermore, we outline uncharted opportunities with GLP‐1 agonism using versatile approaches in selected T1D populations that may inspire and re‐direct future research in this field.